JP2022554267A5 - - Google Patents
Info
- Publication number
- JP2022554267A5 JP2022554267A5 JP2022525193A JP2022525193A JP2022554267A5 JP 2022554267 A5 JP2022554267 A5 JP 2022554267A5 JP 2022525193 A JP2022525193 A JP 2022525193A JP 2022525193 A JP2022525193 A JP 2022525193A JP 2022554267 A5 JP2022554267 A5 JP 2022554267A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- sequence identity
- polypeptide
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928140P | 2019-10-30 | 2019-10-30 | |
| US201962928134P | 2019-10-30 | 2019-10-30 | |
| US62/928,140 | 2019-10-30 | ||
| US62/928,134 | 2019-10-30 | ||
| US202063090520P | 2020-10-12 | 2020-10-12 | |
| US63/090,520 | 2020-10-12 | ||
| PCT/US2020/058247 WO2021087282A1 (en) | 2019-10-30 | 2020-10-30 | Recombinant cdkl5 proteins, gene therapy and production methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022554267A JP2022554267A (ja) | 2022-12-28 |
| JP2022554267A5 true JP2022554267A5 (cg-RX-API-DMAC7.html) | 2023-11-06 |
Family
ID=75716480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525193A Pending JP2022554267A (ja) | 2019-10-30 | 2020-10-30 | 組換えcdkl5タンパク質、遺伝子療法、及び製造方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230043046A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4073231A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022554267A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220106981A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114901802A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020372988A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156506A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202136514A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021087282A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021218703A1 (en) | 2020-02-14 | 2022-07-28 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating CDKL5 deficiency disorder |
| WO2022119890A1 (en) | 2020-12-01 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| KR20240100490A (ko) * | 2021-10-18 | 2024-07-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Cdkl5 결핍 장애(cdd)의 치료에 유용한 조성물 |
| WO2023077143A1 (en) * | 2021-11-01 | 2023-05-04 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
| AU2023288029A1 (en) * | 2022-06-21 | 2025-02-13 | Skyline Therapeutics Limited | Recombinant aav for the gene therapy of sma disease |
| CN116377050A (zh) * | 2022-12-16 | 2023-07-04 | 湖南家辉生物技术有限公司 | 一种发育性癫痫性脑病2型致病基因cdkl5突变位点的应用及其检测试剂和应用 |
| WO2025050032A1 (en) * | 2023-08-31 | 2025-03-06 | Ultragenyx Pharmaceutical Inc. | Methods of producing cdkl5 proteins and uses of the same |
| CN118638212B (zh) * | 2024-06-18 | 2025-07-04 | 河北绶肽生物科技有限公司 | 一种烟草表达的重组人源ⅲ型胶原蛋白及其编码基因和制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2435562A1 (en) * | 2009-05-26 | 2012-04-04 | Biolex Therapeutics, Inc. | Compositions and methods for production of aglycosylated plasminogen |
| HRP20181315T1 (hr) * | 2010-11-22 | 2018-10-19 | Amicus Therapeutics, Inc. | Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| HUE055282T2 (hu) * | 2014-02-28 | 2021-11-29 | Univ Bologna Alma Mater Studiorum | TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása |
| EP3632923A1 (en) * | 2015-01-16 | 2020-04-08 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
| WO2017180587A2 (en) * | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| US20210268072A1 (en) * | 2016-06-28 | 2021-09-02 | Alma Mater Studiorum - Universitá Di Bologna | TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof |
| EP3562494A4 (en) * | 2016-12-30 | 2020-08-19 | The Trustees Of The University Of Pennsylvania | GENE THERAPY FOR THE TREATMENT OF PHENYLKETONURIS |
| US11938197B2 (en) * | 2017-01-10 | 2024-03-26 | The Sydney Children's Hospitals Network (Randwick And Westmead (Incorporating The Royal Alexandra Hospital For Children) | Polynucleotides and vectors for the expression of transgenes |
| EP4585229A3 (en) * | 2017-11-08 | 2026-01-14 | Novartis AG | Means and method for preparing viral vectors and uses of same |
| CN111936624A (zh) * | 2017-11-30 | 2020-11-13 | 阿米库斯治疗学公司 | Cdkl5表达变体和cdkl5融合蛋白 |
| WO2020191241A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| IT201900008877A1 (it) * | 2019-06-13 | 2020-12-13 | Univ Bologna Alma Mater Studiorum | Nuovi costrutti per terapia genica |
-
2020
- 2020-10-30 WO PCT/US2020/058247 patent/WO2021087282A1/en not_active Ceased
- 2020-10-30 JP JP2022525193A patent/JP2022554267A/ja active Pending
- 2020-10-30 AU AU2020372988A patent/AU2020372988A1/en not_active Abandoned
- 2020-10-30 EP EP20881783.3A patent/EP4073231A4/en not_active Withdrawn
- 2020-10-30 US US17/773,416 patent/US20230043046A1/en active Pending
- 2020-10-30 CN CN202080091287.7A patent/CN114901802A/zh active Pending
- 2020-10-30 CA CA3156506A patent/CA3156506A1/en active Pending
- 2020-10-30 TW TW109137883A patent/TW202136514A/zh unknown
- 2020-10-30 KR KR1020227018110A patent/KR20220106981A/ko not_active Withdrawn